Adan Rios is an Oncology physician affiliated with Texas Medical Center. OpenAlex indexes 147 publications with 2,035 citations (h-index 22).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6410 Fannin Ut Oncology
Suite 722
Houston, TX 77030
Telephone
832-325-6520Registry record last updated 4 Feb 2009.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Kite Pharma, Inc.Program year20259 payments
- Janssen Biotech, Inc.Program year20253 payments
- Genmab U.S., Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
44.4%Thalidomide Analog16.3%Revlimid46%Lenalidomide40%Pomalyst14%Part D<11 patientsKinase inhibitor15.1%Calquence79%Iclusig14%Brukinsa7%Part D<11 patients+ 6 more classes in this area
Anti-infectives
37.1%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor10.7%Valacyclovir100%Part D≥30 patientsFluoroquinolone Antibacterial8.4%Levofloxacin100%Part D≥25 patients+ 7 more classes in this area
Metabolism & gastrointestinal
8.9%Corticosteroid3.6%Prednisone100%Part D≥13 patientsPotassium supplement2.5%Potassium Chloride100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1986–1986 per NIH RePORTER. The latest:
- SURAMIN IN PATIENTS WITH AIDS AND AIDS-RELATED ILLNESSES
University of Texas Md Anderson Can Ctr
FY1986N01AI062511
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- T-Cell Prolymphocytic Leukemia With t(X;14)(q28;q11.2): A Clinicopathologic Study of 15 Cases
American Journal of Clinical Pathology
2023 - Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets
Expert Opinion on Investigational Drugs
2023
Similar KOLs
Other experts from the same institution or the same specialty.
James Fleshman, MD
Texas Medical Center
Mark Zafereo, MD
Texas Medical Center
Mihail Chelu, MD, PhD
Texas Medical Center
Anju Bhardwaj, MD
Texas Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”